MEK1在结直肠癌中表达及临床意义

Clinical significance of MEK1 expression in colorectal cancer tissues

目的:探讨有丝分裂原激活的蛋白激酶(MAPK)信号转导途径中MEK1表达与结直肠癌发生及淋巴结和肝转移的关系.方法:采用免疫组化方法,检测86例结直肠癌原发灶、正常结肠黏膜、转移淋巴结和肝转移灶MEK1表达.采用寿命表法分析对比MEK1表达对患者生存的影响.结果:大肠癌原发灶、正常结肠黏膜、转移淋巴结和肝转移灶中MEK1表达阳性率分别为:52.3%,32.6%,71.4%,78.3%.癌原发灶、肝转移灶和转移淋巴结中MEK1表达阳性率高于正常肠黏膜组织(P<0.01).按TNM分期,Ⅲ,Ⅳ期结直肠癌原发灶MEK1表达阳性率高于Ⅰ,Ⅱ期(P<0.01).低分化腺癌和黏液腺癌MEK1表达阳性率高于高-中分化腺癌(P<0.01).MEK1阳性组和MEK1阴性组的3a无病累积生存率分别为41.3%,73.1%.MEK1阳性组患者生存率低于MEK1阴性组,其差异有统计学意义(P<0.05).结论:MEK1增强表达与结直肠癌发生及淋巴结和肝转移有关,检测MEK1表达对判断结直肠癌患者预后有重要意义.

AIM：To investigate expression of MEK1 in colorectal cancer and its association with lymphatic and hepatic metastasis. METHODS：Immunohistochemistry was used to assay MEK1 expression in primary foci,normal colorectal mucosa,metastatic lymph modes and hepatic metastasis in 86 cases of colorectal cancer. RESULTS：The rates of MEK1 expression in primary foci,normal colon mucosa,lymphatic and hepatic metastasis were 52.3%,32.6%,71.4%,and 78.3% respectively. The positive rates of MEK1 in primary foci,lymphatic and hepatic metastasis were higher than that in normal mucosa （ P 〈 0.01 ）. According to TNM stage, the positive rate of MEK1 in stage Ⅲ and Ⅳ was higher than that in stage Ⅰ and Ⅱ （ P 〈 0.01 ）. And a higher rate of MEK1 expression was detected in low differentiation adenocarcinoma and mucus adenocarcinoma than in middle-high differentiation adenocarcinoma （ P 〈 0. 01 ）. The accumulated three-year survival in group of MEK1 positive and negtive was 41.3% and 73. 1%, respectively. And the difference between the groups was significant （P 〈 0. 05 ）. CONCLUSION： Enhanced expression of MEK1 in colorectal cancer was associated significantly with lymphatic and hepatic metastasis. Assaying MEK1 expression has a prognosic value for colorectal cancer patients.